Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (EP2875011) 5-HT3 RECEPTOR ANTAGONISTS

Office : European Patent Office
Application Number: 13742355 Application Date: 16.07.2013
Publication Number: 2875011 Publication Date: 27.05.2015
Publication Kind : B1
Designated States: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Prior PCT appl.: Application Number:US2013050746 ; Publication Number: Click to see the data
IPC:
C07D 221/22
A61K 31/19
A61K 31/5386
C07C 53/18
C07C 53/40
C07D 451/12
C07D 453/02
C07D 471/04
C07D 471/08
C07D 498/08
C07D 519/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
221
Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/-C07D219/187
02
condensed with carbocyclic rings or ring systems
22
Bridged ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5386
spiro-condensed or forming part of bridged ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
53
Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
15
containing halogen
16
Halogenated acetic acids
18
containing fluorine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
53
Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
38
Acyl halides
40
Acetyl halides
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
451
Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
02
containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane; Cyclic acetals thereof
04
with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring system
06
Oxygen atoms
12
acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
453
Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
02
containing not further condensed quinuclidine ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
08
Bridged systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
08
Bridged systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
519
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/ or C07D455/257
CPC:
C07D 221/22
C07D 451/12
C07D 453/02
C07D 471/04
C07D 471/08
C07D 498/08
C07D 519/00
A61K 31/19
A61K 31/5386
C07D 401/14
C07D 403/14
C07D 487/14
C07D 498/04
C07C 53/18
C07C 53/40
Applicants: TAKEDA PHARMACEUTICALS CO
Inventors: HITCHCOCK STEPHEN
MONENSCHEIN HOLGER
REICHARD HOLLY
SUN HUIKAI
KIKUCHI SHOTA
MACKLIN TODD
HOPKINS MARIA
Priority Data: 201261672709 17.07.2012 US
201261708521 01.10.2012 US
2013050746 16.07.2013 US
Title: (DE) 5-HT3-REZEPTORANTAGONISTEN
(EN) 5-HT3 RECEPTOR ANTAGONISTS
(FR) ANTAGONISTES DU RÉCEPTEUR 5-HT3
Abstract:
(EN) The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
(FR) La présente invention concerne des antagonistes du récepteur 5-HT3 de formule (I) qui sont utiles pour le traitement de maladies pouvant être traitées par l'inhibition du récepteur 5-HT3, tels que le vomissement, la douleur, la pharmacodépendance, les troubles neurodégénératifs et psychiatriques, et les troubles gastro-intestinaux. La présente invention concerne en outre des compositions pharmaceutiques contenant de tels composés et des procédés pour préparer de tels composés.
Also published as:
CA2879115IL236702DOP2015000009EA201590228SG11201500302UCN104768943
JP2015522618NZ704814AU2013290375BR112015001028ID2016/04647MYPI 2015000110
PH1/2015/500085VN42301IN957/DELNP/2015ES2659758EP3312169TH180869
TN2015000018WO/2014/014951